Esther Yu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Esther Yu has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Jared Rex Robbins
Department of Radiation Oncology, Duke University, Durham, NC 27710, USA
2 shared publications - Parisa Shamsesfandabadi
Department of Radiation Oncology, Duke University, Durham, NC 27710, USA
2 shared publications - Camden R. Robbins
Department of Radiation Oncology, Duke University, Durham, NC 27710, USA
1 shared publication - David M. Brizel
Department of Head and Neck Surgery & Communication Sciences, Duke University School of Medicine, Durham, North Carolina, USA
1 shared publication - Denise D’ANdrea
Johnson & Johnson, Horsham, USA
1 shared publication - Emily H. Evani
Department of Radiation Oncology, Duke University, 20 Duke Medicine Circle, Durham, NC 27710, USA
1 shared publication
Latest Publications
- Open Access
- 27 October 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (11) , 647
Beyond Prescription Dose: Implant-Site Radiation Dosimetry and Clinical Outcomes of Dental Implants Placed After Head and Neck Radiotherapy—A Systematic Review and Proposed Dosimetric Framework
Background: Dental implants can improve oral rehabilitation following head and neck radiotherapy (RT). The relationship between radiation dose and implant outcomes is not well defined, because specific radiation doses at the implant site are inconsistently reported. Methods: This systematic review evaluated dental implants placed after head and neck RT to determine the impact of the level of radiation dose reporting on outcomes. Studies were assessed for the quality of the reported radiation dosimetry, implant survival, and osteoradionecrosis (ORN). Radiation reporting was classified using a five-level hierarchy ranging from implant-site-specific dosimetry (Level I) to no dose information (Level V). Results: Forty-eight studies met inclusion criteria. Implant-site data (Levels I–II) were reported in 50 Gy and even higher risks above 60 Gy. Conclusions: Dental implantation after head and neck RT can achieve favorable outcomes, but most studies are limited by inadequate evaluation of implant-site radiation dose. Studies evaluating IS radiation dose provide important insights into risk-assessment and implant outcomes. Future studies should report implant-site dose in prospective studies in order to assess and validate useful dose–response thresholds.
- 27 October 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (11) , 647
Open AccessBeyond Prescription Dose: Implant-Site Radiation Dosimetry and Clinical Outcomes of Dental Implants Placed After Head and Neck Radiotherapy—A Systematic Review and Proposed Dosimetric Framework
Background: Dental implants can improve oral rehabilitation following head and neck radiotherapy (RT). The relationship between radiation dose and implant outcomes is not well defined, because specific radiation doses at the implant site are inconsistently reported. Methods: This systematic review evaluated dental implants placed after head and neck RT to determine the impact of the level of radiation dose reporting on outcomes. Studies were assessed for the quality of the reported radiation dosimetry, implant survival, and osteoradionecrosis (ORN). Radiation reporting was classified using a five-level hierarchy ranging from implant-site-specific dosimetry (Level I) to no dose information (Level V). Results: Forty-eight studies met inclusion criteria. Implant-site data (Levels I–II) were reported in 50 Gy and even higher risks above 60 Gy. Conclusions: Dental implantation after head and neck RT can achieve favorable outcomes, but most studies are limited by inadequate evaluation of implant-site radiation dose. Studies evaluating IS radiation dose provide important insights into risk-assessment and implant outcomes. Future studies should report implant-site dose in prospective studies in order to assess and validate useful dose–response thresholds.
- Open Access
- 4 September 2026
- Published by Springer Nature in Oncology and Therapy
- Vol. 14 (3) , 1059-1075
A Qualitative Study of Patient and Caregiver Perspectives on Locally Advanced Head and Neck Cancer in the United States
- 4 September 2026
- Published by Springer Nature in Oncology and Therapy
- Vol. 14 (3) , 1059-1075
Open AccessA Qualitative Study of Patient and Caregiver Perspectives on Locally Advanced Head and Neck Cancer in the United States
- Open Access
Simultaneous Versus Sequential IMRT Boost in the Era of Treatment De-Escalation of Head and Neck Cancers
Radiation therapy is a central component of the definitive and postoperative management for head and neck cancers (HNC), with intensity-modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT) now standard. Within these techniques, two principal boost strategies are used: simultaneous integrated boost (SIB) and sequential boost (SEQ). Although both are guideline-supported, they differ in planning logistics, treatment delivery, potential radiobiologic effects, adaptability to anatomic change, and potential toxicity profiles. In this narrative review, we summarize the key technical, dosimetric, and radiobiologic differences between SIB and SEQ and synthesize the available comparative clinical data, with a focus on their roles in contemporary dose de-escalation strategies. SIB allows for differential dosing within a single plan and potentially shorter overall treatment time but typically delivers higher biologically effective doses (BED) to elective nodal regions. SEQ requires two plans but offers greater flexibility for adaptive replanning, facilitates a lower BED to elective nodal volumes, and may allow for partial normal tissue recovery during the boost phase. Comparative studies, including retrospective series, randomized trials, and a meta-analysis, have not demonstrated consistent differences between SIB and SEQ in survival or local control, with mixed findings regarding toxicity. In the context of de-escalation, multiple prospective studies have successfully used SEQ to reduce elective nodal dose with low rates of elective nodal failure, while recent data suggest that SIB-based elective dose reduction may also be feasible in select settings. Overall, both SIB and SEQ are effective boost strategies in HNC radiotherapy. While practice is often driven by institutional workflow and clinician preference, emerging evidence suggests potential advantages of SEQ for elective nodal dose de-escalation. Further prospective studies are needed to better define the relative impacts of SIB and SEQ on toxicity and tumor control.
Open AccessSimultaneous Versus Sequential IMRT Boost in the Era of Treatment De-Escalation of Head and Neck Cancers
Radiation therapy is a central component of the definitive and postoperative management for head and neck cancers (HNC), with intensity-modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT) now standard. Within these techniques, two principal boost strategies are used: simultaneous integrated boost (SIB) and sequential boost (SEQ). Although both are guideline-supported, they differ in planning logistics, treatment delivery, potential radiobiologic effects, adaptability to anatomic change, and potential toxicity profiles. In this narrative review, we summarize the key technical, dosimetric, and radiobiologic differences between SIB and SEQ and synthesize the available comparative clinical data, with a focus on their roles in contemporary dose de-escalation strategies. SIB allows for differential dosing within a single plan and potentially shorter overall treatment time but typically delivers higher biologically effective doses (BED) to elective nodal regions. SEQ requires two plans but offers greater flexibility for adaptive replanning, facilitates a lower BED to elective nodal volumes, and may allow for partial normal tissue recovery during the boost phase. Comparative studies, including retrospective series, randomized trials, and a meta-analysis, have not demonstrated consistent differences between SIB and SEQ in survival or local control, with mixed findings regarding toxicity. In the context of de-escalation, multiple prospective studies have successfully used SEQ to reduce elective nodal dose with low rates of elective nodal failure, while recent data suggest that SIB-based elective dose reduction may also be feasible in select settings. Overall, both SIB and SEQ are effective boost strategies in HNC radiotherapy. While practice is often driven by institutional workflow and clinician preference, emerging evidence suggests potential advantages of SEQ for elective nodal dose de-escalation. Further prospective studies are needed to better define the relative impacts of SIB and SEQ on toxicity and tumor control.